Label (71610 0799 30)
Pregabalin Capsule
Product Images NDC 71610-799
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-799). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Chemical Structure (Pregabalin 01)
Figure 1 (Pregabalin 02)
This text provides information on the percentage of patients improved with different doses of Pregabalin and a placebo. The data displays the percentage improvement in pain from baseline for each treatment option.*
Figure 2 (Pregabalin 03)
Figure 3 (Pregabalin 04)
This text provides information on a clinical trial involving the use of Pregabalin at different dosages and a Placebo. The dosages evaluated were 300 mg two times a day, 150 mg two times a day, and 75 mg two times a day. The results show the percentage of patients improved and the percent improvement in pain from the baseline.*
Figure 4 (Pregabalin 05)
This text provides information about the percentage of patients who improved with different treatments for pain relief. The treatments mentioned include Pregabalin at doses of 100 mg and 200 mg three times a day, as well as a placebo. The percentage improvement in pain from baseline is also indicated at various points, such as 10%, 20%, 50%, 70%, 80%, and 90%.*
Figure 5 (Pregabalin 06)
This text provides information on the percent of patients improved with different dosages of Pregabalin and a placebo. It shows the percentage improvement in pain from the baseline with Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and the placebo.*
Figure 6 (Pregabalin 07)
This is not readable.*
Figure 7 (Pregabalin 08)
This document appears to be a table showing different studies (E1, E2, E3) and their corresponding tested doses in milligrams per day. The studies were conducted with varying dose levels, including Placebo, and only significant p-values are shown. The text also includes some numerical values and symbols related to the studies.*
Figure 9 (Pregabalin 09)
This is not a readable text.*
Figure 10 (Pregabalin 10)
Figure 11 (Pregabalin 11)
The text provides information about the percentage of subjects who showed improvement over a 12-week period when comparing Pregabalin to Placebo. This data is represented with numerical values ranging from 210 to 290, with a peak improvement of 100% reported.*
Figure 12 (Pregabalin 12)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
